HK1258724A1 - 選擇白血病對象的治療方案的分析和方法 - Google Patents

選擇白血病對象的治療方案的分析和方法

Info

Publication number
HK1258724A1
HK1258724A1 HK19101125.5A HK19101125A HK1258724A1 HK 1258724 A1 HK1258724 A1 HK 1258724A1 HK 19101125 A HK19101125 A HK 19101125A HK 1258724 A1 HK1258724 A1 HK 1258724A1
Authority
HK
Hong Kong
Prior art keywords
leukemia
assays
selecting
subject
methods
Prior art date
Application number
HK19101125.5A
Other languages
English (en)
Inventor
Max Gordon
Paul Tardi
Jeffrey Tyner
Lawrence Mayer
Original Assignee
Celator Pharmaceuticals Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc, Univ Oregon Health & Science filed Critical Celator Pharmaceuticals Inc
Publication of HK1258724A1 publication Critical patent/HK1258724A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK19101125.5A 2015-11-11 2019-01-22 選擇白血病對象的治療方案的分析和方法 HK1258724A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254109P 2015-11-11 2015-11-11
PCT/US2016/061444 WO2017083592A1 (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Publications (1)

Publication Number Publication Date
HK1258724A1 true HK1258724A1 (zh) 2019-11-15

Family

ID=58695625

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101125.5A HK1258724A1 (zh) 2015-11-11 2019-01-22 選擇白血病對象的治療方案的分析和方法

Country Status (15)

Country Link
US (3) US10927418B2 (zh)
EP (1) EP3373919A4 (zh)
JP (2) JP6976941B2 (zh)
KR (1) KR20180108572A (zh)
CN (2) CN108778260A (zh)
AU (2) AU2016353163B2 (zh)
BR (1) BR112018009463A8 (zh)
CA (2) CA3005076C (zh)
CO (1) CO2018005846A2 (zh)
HK (1) HK1258724A1 (zh)
IL (2) IL292080B2 (zh)
MX (2) MX2018005771A (zh)
MY (1) MY193531A (zh)
SG (2) SG10202112699UA (zh)
WO (1) WO2017083592A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292080B2 (en) * 2015-11-11 2024-09-01 Celator Pharmaceuticals Inc Treatment regimens for hematological cancers and methods for their use
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. TREATMENT OF LOW INTENSITY HEMATOLOGICAL DISORDERS
WO2020102595A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN111870600B (zh) * 2020-07-13 2022-04-15 中南大学湘雅二医院 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
KR20240128987A (ko) 2021-12-30 2024-08-27 바이오메아 퓨전, 인크. Flt3의 억제제로서의 피라진 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1744764B1 (en) 2004-04-22 2012-05-30 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
CN100391437C (zh) * 2005-09-12 2008-06-04 重庆医科大学附属第二医院 抗急性髓性白血病的gm-csf靶向药物脂质体及制备方法
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
CN101657098A (zh) * 2007-02-16 2010-02-24 切拉托尔制药公司 用于治疗造血性癌症和增殖性病症的固定药物比例
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
MX2011012267A (es) 2009-05-19 2012-04-11 Vivia Biotech Sl Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos.
WO2012006584A2 (en) * 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Therapeutic regimens for hedgehog-associated cancers
KR20220141906A (ko) * 2011-10-21 2022-10-20 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
CN104508143A (zh) * 2012-03-12 2015-04-08 纪念斯隆-凯特琳癌症中心 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2014087018A1 (en) 2012-12-07 2014-06-12 Evotec (München) Gmbh Markers for responsiveness to an inhibitor of flt3
CA2960824A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
IL292080B2 (en) * 2015-11-11 2024-09-01 Celator Pharmaceuticals Inc Treatment regimens for hematological cancers and methods for their use
EP3856198A4 (en) * 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. TREATMENT OF LOW INTENSITY HEMATOLOGICAL DISORDERS

Also Published As

Publication number Publication date
MX2018005771A (es) 2019-03-14
RU2018121249A3 (zh) 2020-03-17
CA3219061A1 (en) 2017-05-18
EP3373919A4 (en) 2019-06-19
AU2016353163A1 (en) 2018-06-07
JP7504070B2 (ja) 2024-06-21
WO2017083592A1 (en) 2017-05-18
BR112018009463A2 (pt) 2018-11-06
CO2018005846A2 (es) 2018-08-21
CN108778260A (zh) 2018-11-09
SG11201804020YA (en) 2018-06-28
CA3005076C (en) 2024-01-02
CN115414376A (zh) 2022-12-02
US10927418B2 (en) 2021-02-23
EP3373919A1 (en) 2018-09-19
JP6976941B2 (ja) 2021-12-08
IL292080B1 (en) 2024-05-01
US20210246512A1 (en) 2021-08-12
SG10202112699UA (en) 2021-12-30
US20180327854A1 (en) 2018-11-15
IL292080B2 (en) 2024-09-01
BR112018009463A8 (pt) 2019-02-26
JP2018535975A (ja) 2018-12-06
AU2022291559A1 (en) 2023-02-02
IL259271A (en) 2018-07-31
IL292080A (en) 2022-06-01
IL259271B (en) 2022-05-01
CA3005076A1 (en) 2017-05-18
JP2022024031A (ja) 2022-02-08
US20230279503A1 (en) 2023-09-07
KR20180108572A (ko) 2018-10-04
RU2018121249A (ru) 2019-12-17
US11746386B2 (en) 2023-09-05
MY193531A (en) 2022-10-18
MX2024003980A (es) 2024-04-29
AU2016353163B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
HK1245031A1 (zh) 具有多種材料的編織鞋面
IL241156A0 (en) Tests and methods for choosing treatment methods for those with depression
HK1258724A1 (zh) 選擇白血病對象的治療方案的分析和方法
PL3230463T3 (pl) Szybkie przetwarzanie wstępne
AU201613057S (en) Luggage with handle down
PL3167205T3 (pl) Łącznik blokujący z zamknięciem obrotowym
GB201616683D0 (en) Appatatus for sorting gemstones
GB2552640B (en) Tool for use with a fastener
IL247084A0 (en) dose fgh–18
AU365134S (en) Bottle with owl shape
SG11201705238VA (en) Scheduling interaction with a subject
GB2571222B (en) Synthetic-image device with interlock features
GB201418710D0 (en) Dosage regimen
GB202116438D0 (en) Jig with slot template
SG11201710829WA (en) Albumin-sugar chain complex
PL2946646T3 (pl) Urządzenie wyposażone w mechanizm blokujący
PL3102587T3 (pl) Nieutwardzone wyroby o ulepszonym okresie trwałości
RS59096B1 (sr) Ispitni sto za odvijač sa poboljšanom kontrolom
PL3034727T3 (pl) Zamek ze sztywnym łańcuchem
GB201417786D0 (en) A jig
GB2523749B (en) A self-weighing luggage device
GB201614232D0 (en) Regimen
GB201713224D0 (en) Regimen
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen